Did CEOs and officers buy or sell their own stock?
Open-market trades by the people who know the company best, with their own money.
Last 7 days: the stocks insiders bought and sold most
Stocks Koreans hold most · disclosed Last 7 days · open-market trades only
Bought most
Sold most
Whalegun
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Lenz TherapeuticsLENZ | Open-market buy | 03/27 | 03/30 | 7,500 sh | $8.57 | $64,275 | +139.2% | |
Evert B. SchimmelpenninkPresident, CEO and Secretary | Lenz TherapeuticsLENZ | Open-market buy | 03/27 | 03/30 | 28,089 sh | $8.95 | $251,396.55 | +57.1% |
Jeffrey P. GeorgeDirector | Lenz TherapeuticsLENZ | Open-market buy | 03/27 | 03/30 | 5,592 sh | $8.92 | $49,880.64 | No record |
Lenz TherapeuticsLENZ | Open-market sale10b5-1 plan | 25/11/17 | 25/11/19 | 10,000 sh2 trades | $26.10avg. | $261,046.44 | −67.9% | |
James W. McCollumDirector | Lenz TherapeuticsLENZ | Open-market buy | 25/11/07 | 25/11/10 | 10,500 sh | $22.79 | $239,295 | No record |
Lenz TherapeuticsLENZ | Open-market buy | 25/11/07 | 25/11/07 | 2,198 sh2 trades | $22.76avg. | $50,025.48 | +68.9% | |
Lenz TherapeuticsLENZ | Open-market sale | 25/09/30 | 25/10/02 | 224,974 sh6 trades | $46.01avg. | $10,352,070.98 | No record | |
Lenz TherapeuticsLENZ | Open-market sale | 25/09/18 | 25/09/22 | 135,304 sh6 trades | $42.23avg. | $5,714,064.91 | No record | |
Lenz TherapeuticsLENZ | Open-market sale | 25/08/22–25/08/26 | 25/08/26 | 188,094 sh12 trades | $39.47avg. | $7,423,963.67 | No record | |
Lenz TherapeuticsLENZ | Open-market sale | 25/08/15–25/08/18 | 25/08/19 | 260,713 sh4 trades | $39.34avg. | $10,255,193.28 | No record | |
Versant Venture Capital VI10% Owner | Lenz TherapeuticsLENZ | Open-market sale | 25/07/10 | 25/07/14 | 191,376 sh | $34.00 | $6,506,784 | −10.8% |
Versant Venture Capital VI10% Owner | Lenz TherapeuticsLENZ | Open-market sale | 25/06/27 | 25/07/01 | 200,000 sh | $30.47 | $6,094,000 | −10.2% |
Lenz TherapeuticsLENZ | Open-market sale | 25/06/18–25/06/20 | 25/06/20 | 334,801 sh3 trades | $30.19avg. | $10,107,817.95 | No record | |
Versant Venture Capital VI10% Owner | Lenz TherapeuticsLENZ | Open-market sale | 25/06/10 | 25/06/12 | 350,000 sh | $29.00 | $10,150,000 | −21.9% |
Lenz TherapeuticsLENZ | Open-market buy | 24/05/14 | 24/05/15 | 3,188 sh | $15.68 | $49,987.84 | No record | |
James W. McCollumDirector | Lenz TherapeuticsLENZ | Open-market buy | 24/05/13 | 24/05/14 | 31,332 sh | $15.99 | $500,998.68 | +6.3% |
Lenz TherapeuticsLENZ | Open-market buy | 24/03/21 | 24/03/25 | 998,009 sh2 trades | $15.03avg. | $15,000,075.27 | No record |